# A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects

> **NCT06161220** · PHASE1 · COMPLETED · sponsor: **Impax Laboratories, LLC** · enrollment: 35 (actual)

## Conditions studied

- Cardiac Repolarization in Healthy Subjects

## Interventions

- **DRUG:** Carbidopa capsule
- **DRUG:** Moxifloxacin Tablets, USP
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06161220
- **Lead sponsor:** Impax Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-30
- **Primary completion:** 2023-12-03
- **Final completion:** 2023-12-05
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06161220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06161220, "A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06161220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*